Tomas J. Philipson, PhD

Articles by Tomas J. Philipson, PhD

The Social Value of Childhood Vaccination in the United States

ByTomas J. Philipson, PhD,Julia Thornton Snider, PhD,Ayman Chit, PhD,Sarah Green, BA,Philip Hosbach, BA,Taylor Tinkham Schwartz, MPH,Yanyu Wu, PhD,Wade M. Aubry, MD

December 5th 2016

Vaccination of children born in the United States in 2009 will save 1.2 million quality-adjusted life-years, generating $184 billion in social value net of vaccination costs.

The Wider Public Health Value of HCV Treatment Accrued by Liver Transplant Recipients

ByAnupam B. Jena, MD, PhD,Warren Stevens, PhD,Yuri Sanchez Gonzalez, PhD,Steven E. Marx, PharmD,Timothy Juday, PhD,Darius N. Lakdawalla, PhD,Tomas J. Philipson, PhD

May 3rd 2016

Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non—HCV-mediated liver failure.

Impact of Oral Nutritional Supplementation on Hospital Outcomes

ByTomas J. Philipson, PhD,Julia Thornton Snider, PhD,Darius N. Lakdawalla, PhD,Benoit Stryckman, MA,Dana P. Goldman, PhD

February 13th 2013

Instrumental variables regression analysis indicated that inpatient oral nutritional supplement use decreased length of stay, episode cost, and 30-day readmission probability.

Pharmacy Cost Sharing, Antiplatelet Therapy Utilization, and Health Outcomes for Patients With Acute Coronary Syndrome

ByTomas J. Philipson, PhD,Essy Mozaffari, PharmD, MPH,John Ross Maclean, MD

April 7th 2010

This article studies the association of pharmacy cost sharing with antiplatelet therapy utilization and health outcomes for patients with acute coronary syndrome.